




The relative strengths and weaknesses of Karyopharm Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Karyopharm Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 221%, being 29% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	334,612
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,904
Liabilities, Non-Current	0
Other Assets	2,717
Other Compr. Net Income	-27
Other Expenses	26
Other Liabilities	111,118
Other Net Income	1,502
Other Revenues	30,336
Property and Equipment	3,863
Research and Development	161,372
Selling, General and Administrative Expense	48,847

Output Variable	Value in 1000 USD
Assets	341,192
Liabilities	158,022
Expenses	210,245
Revenues	30,336
Stockholders Equity	183,170
Net Income	-178,407
Comprehensive Net Income	-178,420
BaseVar	370,662
ECR before LimitedLiability	88%
Economic Capital Ratio	221%